ANTIPSYCHOTICS PRIOR AUTHORIZATION FORM







(form effective 1/8/2024)

Fax to PerformRx $^{\text{SM}}$ at **1-855-851-4058**, or to speak to a representative, call **1-888-674-8720**.

PRIOR AUTHORIZATION REQUEST INFORMATION						
☐ New request ☐ Renev	val request Total pages:	Office contact/phone:			LTC facility contact/phone:	
PATIENT INFORMATION						
Patient name:	Patient ID#:		l au	DOB:		
Street address:		Apt #	:	City/state/zip:		
PRESCRIBER INFOR	MATION					
Prescriber name: Specialty:		NPI	•		State license #:	
Street address:		Suite		City/state/zip:	otato noonoo n.	
Phone: Fax:						
MEDICATION REQUESTED						
Preferred Agents Abilify Asimtufii Abilify Maintena aripiprazole tablet Aristada ER injection Aristada Initio injection clozapine tablet	☐ fluphenazine oral concentrat☐ fluphenazine tablet☐ fluphenazine decan. inj.☐ haloperidol tablet☐ haloperidol decanoate inj.☐ haloperidol lactate inj.	e haloperidol lactate oral concentrate Invega Hafyera Invega Sustenna Invega Trinza loxapine capsule	□ lurasidor □ olanzapin □ paliperide □ perphena □ Perseris □ quetiapin	ne tablet one ER tab azine tablet ER injection	☐ quetiapine ER tablet☐ Risperdal Consta☐ risperidone solution☐ risperidone tablet☐ trifluoperazine tablet☐	□ ziprasidone capsule □ Zyprexa Relprevv
Non-Preferred Agents Abilify Mycite Abilify tablet Abilify tablet Adasuve inhalation antiriptyline/perphenazine aripiprazole ODT aripiprazole solution asenapine SL Caplyta capsules	☐ chlorpromazine inj. ☐ chlorpromazine solution ☐ chlorpromazine tablet ☐ clozapine ODT ☐ Clozaril tablet ☐ Fanapt tablet ☐ fluphenazine elixir ☐ fluphenazine HCl injection	☐ Geodon capsule ☐ Geodon injection ☐ Haldol decanoate inj. ☐ Invega ER tablet ☐ Latuda tablet ☐ Lybalvi ☐ molindone tablet ☐ Nuplazid capsule	□ pimozide □ Rexulti t	ne inj/ODT ne/fluoxetine cap e tablet ablet al solution/tablet one ODT	□ Secuado patch □ Seroquel tablet □ Seroquel XR tablet □ Symbyax capsule □ thioridazine tablet □ thiothixene capsule □ Uzedy ER	□ Versacloz suspension □ Vraylar capsule □ Ziprasidone inj. □ Zyprexa tablet/injection □ Zyprexa Zydis □ other:
Strength: Diagnosis:	Dosage form:	Directions:			Quantity: Diagnosis code (required):	Refills:
PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication):						
Deliver to: Patient's Home Physician's Office Patient's Preferred Pharmacy Name:						
Pharmacy Phone #: Pharmacy Fax #:						
☐ I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.						
REQUEST FOR A NON-PREFERRED AGENT						
1. Has the patient taken the requested non-preferred antipsychotic in the past 90 days? Yes — Submit documentation. No						
2. Has the patient tried and failed the preferred medications (listed above)? ☐ Yes − List medications tried: ☐ No 3. Does the patient have a contraindication or intolerance to the preferred medications? ☐ Yes − Submit documentation of contraindication/intolerance. ☐ No						
REQUEST FOR A PATIENT LESS THAN 18 YEARS OF AGE						
4. For renewal requests, has the patient had improvement in target symptoms with use of this medication? Yes No						
5. Is this request for a dose increase of a previously approved medication or request over the plan limits? Yes – Submit recent chart documentation and/or treatment guidelines supporting the requested dose.						
6. For renewal requests, is there a plan for taper/discontinuation or rationale for continued use of requested drug? 🗆 Yes Submit supporting documentation. 🗆 No						
7. Is the requested agent prescribed by, or in consultation with, one of the following physician specialists? ☐ Yes ☐ No Submit documentation of consultation, if applicable. ☐ child development pediatrician ☐ child & adolescent psychiatrist ☐ general psychiatrist (only if patient is ≥ 14 years of age) ☐ pediatric neurologist						
8. Does the patient have severe symptoms related to a psychotic or neuro-developmental disorder? Yes – Submit medical record documentation.						
9. Has chart documented evidence of comprehensive evaluation and plan of care that includes non-drug therapies? Yes – Submit medical record documentation.						
10. Has the patient had the following baseline and/or follow-up monitoring? Check all that apply. BMI and/or weight (for follow-up monitoring this must be done quarterly) Display blood pressure Fasting blood glucose or hemoglobin a1c Fasting lipid panel Presence of extrapyramidal symptoms (EPS) using the Abnormal Involuntary Movement Scale (AIMS) Submit documentation of all monitoring/test results and dates.						
REQUEST FOR THERAPEUTIC DUPLICATION OF AN ATYPICAL OR TYPICAL ANTIPSYCHOTIC						
11. Does the patient have a medical reason for concomitant use of the requested medications? \square Yes – Submit documentation of treatment guidelines supporting concomitant use. \square No						
12. Is this request for a drug that is being titrated to, or tapered from, a drug in the same class? No						
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION						
Prescriber signature: Date:						

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.